Aphaia's scientific approach is so different from the mainstream that they couldn't rely on existing market understanding. Their co-founder actively toured conferences and participated in interviews to tell their story repeatedly. This educational campaign was crucial for building trust and getting stakeholders to "buy into" their completely new therapeutic concept.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Instead of marketing directly to individuals struggling to afford training, partner with the institutions they are already paying. This provides access to a stream of customers who have already demonstrated financial commitment.

Beyond pitching to investors, biotech conferences like BioEquity Europe offer emerging companies a critical opportunity to connect with industry analysts and media. This builds relationships that lead to inclusion in market analysis and content, providing invaluable visibility and third-party validation.

For complex technologies like Transel's DART platform, the most effective sales strategy is demonstrating value directly through proof-of-concept (POC) projects. Successful POCs naturally lead to larger paid work orders and create internal advocacy within client organizations, creating a powerful pull effect.

Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.

Unlike incumbents, new biotech and pharma companies often lack established sales forces. They launch with a 'digital first' go-to-market strategy, turning to platforms like Doximity early in their lifecycle. This creates a new and rapidly growing customer segment for Doximity, independent of the incumbents' slower transition.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

Many organizations mistakenly view partner marketing as a series of disconnected activities like webinars. True partner marketing is a comprehensive go-to-market strategy that defines the end-to-end plan for launching joint solutions and messages.